Telehealth acquisitions raising ARPU
Ro and the telehealth capital cycle
Acquisition became the fastest way for telehealth companies to escape the low value math of one symptom, one prescription businesses. A company that starts with ED, hair loss, or basic urgent care often makes only a small monthly amount from each patient and loses many of them quickly. Buying a chronic care, diagnostics, or fertility asset adds more visits, tests, coaching, and pharmacy spend into the same relationship, which is how ARPU starts to move materially.
-
Teladoc buying Livongo was the clearest example. Teladoc had broad virtual care access, while Livongo added higher value chronic condition management for diabetes and other ongoing needs. The logic was to sell a much bigger care bundle to the same employers and health plans, not just isolated visits.
-
Ro buying Modern Fertility and Thirty Madison folding in Nurx show the same pattern in D2C telehealth. Instead of selling mostly to men for ED or hair loss, they widened into women’s health, fertility, and birth control, categories with more repeat touchpoints, lab work, and stronger reasons to stay on platform.
-
There is a practical limit to this strategy. Multi specialty rollups can raise revenue per patient, but they are hard to integrate because clinical workflows, software stacks, and provider operations differ by specialty. That is why the winners tend to pair expansion with owned infrastructure like labs, pharmacy, or in home care, not just brand aggregation.
The next phase is moving from category bundles to full care loops. Telehealth companies that can combine diagnosis, testing, prescribing, monitoring, and refill or follow up inside one workflow will keep lifting revenue per patient. The market is heading toward fewer, broader platforms that own more of the care journey for specific high value conditions.